[1] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature, 1988,332:411-415. [2] Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family:three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA, 1989,86:2863-2867. [3] Rubanyi CM, Polokoff MA. Endothelin:molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.Pharmacol Rev, 1994,46:325-415. [4] Falanga V, Katz MH, Kirsner R, et al. The effects of endothelin-1 on human dermal fibroblast growth and synthetic activity. J Surg Res, 1992,53:515-519. [5] Bull HA, Bunker CB, Terenghi G, et al. Endothelin-1 in human skin:immunolcalization, receptor binding, mRNA expression, and effects on cutaneous microvascular endothelial cells. J Invest Dermatol, 1991,97:618-623. [6] Vancheeswaran R, Azam A, Black C, et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol, 1994,21:1268-1276. [7] Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis:immunoelectron microscopic study. Int J Dermatol, 1997,36:272-275. [8] Imaizumi T, Jean-Louis F, Dubertret ML, et al. Effect of human basic fibroblast growth factor on fibroblast proliferation,cell volume, collagen lattice contraction:in comparison with acidic type. J Dermatol Sci, 1996,11:134-141. [9] Tan EM, Hoffren J, Rouda S, et al. Decorin, versican, and biglycan gene expression by keloid and normal dermal fibroblasts:differential regulation by basic fibroblast growth factor. Exp Cell Res, 1993,209:200-207. |